Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.
Total raised: $140M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2024 | Series A | $140M | - |
Mentions in press and media 5
| Date | Title | Description |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 19.12.2024 | Ottimo Pharma Raises Over $140M | Ottimo Pharma, a NYC-based private biotech company, raised over $140M in funding. The round was led by OrbiMed, Avoro Capital, Samsara BioCapital. Other investors included RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Mo... |
| 28.10.2024 | Ottimo Pharma Emerges from Stealth with Funding from Medicxi and Management Team | Ottimo Pharma, a Sandwich, UK-based private biotech company developing cancer therapies, emerged from stealth with funding from Medicxi and management team. The amount of the deal was not disclosed. The company intends to use the funds to e... |
| - | Ottimo Pharma | “Ottimo Pharma – Pioneering bi-functional medicines to extend the lives of people living with cancer.” |